- TRADE NAME: Fetroja (Shionogi)
- INDICATIONS: Treatment of patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible Gram-negative microorganisms.
- CLASS: Antibiotic, Antibiotic; beta-lactam, Antimicrobial, Cephalosporin, Cephalosporin; 4th generation
- HALF-LIFE: 2–3 hours
- FDA APPROVAL DATE: 11/14/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: There are no available data on cefiderocol use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 10/22/2024
